Adial Pharmaceuticals Completes Successful FDA Meeting for Phase 3 Trial of AD04 for Alcohol Use Disorder Treatment.

Adial Pharmaceuticals completed a successful End of Phase 2 meeting with the FDA, marking a major step towards the Phase 3 AD04 trial launch. The FDA provided input into the trial design, and the company is now prepared to advance its lead investigational drug, AD04, into Phase 3 clinical development for the treatment of Alcohol Use Disorder. The FDA's feedback is expected to strengthen Adial's position in partnership discussions, as regulatory clarity is a key consideration for potential collaborators.